India · Delayed Price · Currency is INR MedPlus Health Services Statistics
Total Valuation
NSE:MEDPLUS has a market cap or net worth of INR 80.48 billion. The enterprise value is 88.59 billion.
| Market Cap | 80.48B |
| Enterprise Value | 88.59B |
Important Dates
The next estimated earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:MEDPLUS has 120.14 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Current Share Class | 120.14M |
| Shares Outstanding | 120.14M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 13.29% |
| Owned by Institutions (%) | 45.03% |
| Float | 71.24M |
Valuation Ratios
The trailing PE ratio is 38.24 and the forward PE ratio is 36.97. NSE:MEDPLUS's PEG ratio is 1.95.
| PE Ratio | 38.24 |
| Forward PE | 36.97 |
| PS Ratio | 1.11 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 4.18 |
| P/FCF Ratio | 21.60 |
| P/OCF Ratio | 16.24 |
| PEG Ratio | 1.95 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.79, with an EV/FCF ratio of 23.78.
| EV / Earnings | 42.09 |
| EV / Sales | 1.23 |
| EV / EBITDA | 14.79 |
| EV / EBIT | 28.15 |
| EV / FCF | 23.78 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 2.38 |
| Debt / FCF | 3.82 |
| Interest Coverage | 2.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.96% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | 2.50M |
| Profits Per Employee | 72,897 |
| Employee Count | 28,872 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:MEDPLUS has paid 540.11 million in taxes.
| Income Tax | 540.11M |
| Effective Tax Rate | 20.42% |
Stock Price Statistics
The stock price has decreased by -19.75% in the last 52 weeks. The beta is 0.46, so NSE:MEDPLUS's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -19.75% |
| 50-Day Moving Average | 719.41 |
| 200-Day Moving Average | 812.03 |
| Relative Strength Index (RSI) | 44.00 |
| Average Volume (20 Days) | 199,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:MEDPLUS had revenue of INR 72.29 billion and earned 2.10 billion in profits. Earnings per share was 17.52.
| Revenue | 72.29B |
| Gross Profit | 18.65B |
| Operating Income | 3.15B |
| Pretax Income | 2.64B |
| Net Income | 2.10B |
| EBITDA | 3.95B |
| EBIT | 3.15B |
| Earnings Per Share (EPS) | 17.52 |
Balance Sheet
The company has 6.13 billion in cash and 14.24 billion in debt, with a net cash position of -8.11 billion or -67.54 per share.
| Cash & Cash Equivalents | 6.13B |
| Total Debt | 14.24B |
| Net Cash | -8.11B |
| Net Cash Per Share | -67.54 |
| Equity (Book Value) | 19.75B |
| Book Value Per Share | 164.55 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 4.96 billion and capital expenditures -1.23 billion, giving a free cash flow of 3.73 billion.
| Operating Cash Flow | 4.96B |
| Capital Expenditures | -1.23B |
| Depreciation & Amortization | 803.07M |
| Net Borrowing | -1.45B |
| Free Cash Flow | 3.73B |
| FCF Per Share | 31.01 |
Margins
Gross margin is 25.80%, with operating and profit margins of 4.35% and 2.91%.
| Gross Margin | 25.80% |
| Operating Margin | 4.35% |
| Pretax Margin | 3.66% |
| Profit Margin | 2.91% |
| EBITDA Margin | 5.46% |
| EBIT Margin | 4.35% |
| FCF Margin | 5.41% |
Dividends & Yields
NSE:MEDPLUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | -0.00% |
| Earnings Yield | 2.62% |
| FCF Yield | 4.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:MEDPLUS is 1,013.14, which is 51.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1,013.14 |
| Price Target Difference | 51.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 14.62% |
| EPS Growth Forecast (3Y) | 5.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |